News

iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor

Further evaluation of IDO1 inhibitor with clinically manageable safety profile to commence following review of Phase 1 clinical data and trial design

Gosselies, Belgium – January 4, 2017 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that it has regained exclusive worldwide rights from Pfizer to develop and commercialise EOS200271, a highly selective, clinical-stage IDO1 inhibitor. 

Read more

iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting

Presentations to highlight new preclinical results for A2A antagonist and TIGIT antibody programs

Gosselies, Belgium – November 6, 2017 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the presentation of posters on its novel A2A receptor antagonist and TIGIT antibody programs, at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, taking place from November 8-12, 2017 in National Harbor, Maryland.

Read more